| Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism M Hesse, M Modolell, AC La Flamme, M Schito, JM Fuentes, AW Cheever, ... The Journal of Immunology 167 (11), 6533-6544, 2001 | 1007 | 2001 |
| CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal O Schulz, AD Edwards, M Schito, J Aliberti, S Manickasingham, A Sher, ... Immunity 13 (4), 453-462, 2000 | 724 | 2000 |
| Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test SD Lawn, P Mwaba, M Bates, A Piatek, H Alexander, BJ Marais, ... The Lancet infectious diseases 13 (4), 349-361, 2013 | 627 | 2013 |
| CCR5 provides a signal for microbial induced production of IL-12 by CD8α+ dendritic cells J Aliberti, C Reis e Sousa, M Schito, S Hieny, T Wells, GB Huffnagle, ... Nature immunology 1 (1), 83-87, 2000 | 439 | 2000 |
| New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects AI Zumla, SH Gillespie, M Hoelscher, PPJ Philips, ST Cole, I Abubakar, ... The Lancet infectious diseases 14 (4), 327-340, 2014 | 427 | 2014 |
| Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts BJ Marais, K Lönnroth, SD Lawn, GB Migliori, P Mwaba, P Glaziou, ... The Lancet infectious diseases 13 (5), 436-448, 2013 | 392 | 2013 |
| Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues CJ Meehan, GA Goig, TA Kohl, L Verboven, A Dippenaar, M Ezewudo, ... NATURE reviews microbiology 17 (9), 533-545, 2019 | 377 | 2019 |
| Drug-resistant tuberculosis: time for visionary political leadership I Abubakar, M Zignol, D Falzon, M Raviglione, L Ditiu, S Masham, I Adetifa, ... The Lancet infectious diseases 13 (6), 529-539, 2013 | 375 | 2013 |
| A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis P Miotto, B Tessema, E Tagliani, L Chindelevitch, AM Starks, C Emerson, ... European Respiratory Journal 50 (6), 2017 | 363 | 2017 |
| Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing CRyPTIC Consortium and the 100,000 Genomes Project New England Journal of Medicine 379 (15), 1403-1415, 2018 | 344 | 2018 |
| Clinical case definitions for classification of intrathoracic tuberculosis in children: an update SM Graham, LE Cuevas, P Jean-Philippe, R Browning, M Casenghi, ... Clinical Infectious Diseases 61 (suppl_3), S179-S187, 2015 | 330 | 2015 |
| Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers RS Wallis, M Maeurer, P Mwaba, J Chakaya, R Rustomjee, GB Migliori, ... The Lancet infectious diseases 16 (4), e34-e46, 2016 | 320 | 2016 |
| Tuberculosis biomarkers discovery: developments, needs, and challenges RS Wallis, P Kim, S Cole, D Hanna, BB Andrade, M Maeurer, M Schito, ... The Lancet infectious diseases 13 (4), 362-372, 2013 | 301 | 2013 |
| Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities R McNerney, M Maeurer, I Abubakar, B Marais, TD Mchugh, N Ford, ... Journal of Infectious Diseases 205 (suppl_2), S147-S158, 2012 | 279 | 2012 |
| Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review SHE Kaufmann, C Lange, M Rao, KN Balaji, M Lotze, M Schito, AI Zumla, ... The Lancet Respiratory Medicine 2 (4), 301-320, 2014 | 264 | 2014 |
| Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects M Pai, M Schito The Journal of infectious diseases 211 (suppl_2), S21-S28, 2015 | 239 | 2015 |
| Drug-resistant tuberculosis—current dilemmas, unanswered questions, challenges, and priority needs A Zumla, I Abubakar, M Raviglione, M Hoelscher, L Ditiu, TD Mchugh, ... Journal of Infectious Diseases 205 (suppl_2), S228-S240, 2012 | 220 | 2012 |
| Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project M Zignol, AS Dean, N Alikhanova, S Andres, AM Cabibbe, DM Cirillo, ... The Lancet infectious diseases 16 (10), 1185-1192, 2016 | 217 | 2016 |
| Paralysis of dendritic cell IL-12 production by microbial products prevents infection-induced immunopathology CR e Sousa, G Yap, O Schulz, N Rogers, M Schito, J Aliberti, S Hieny, ... Immunity 11 (5), 637-647, 1999 | 207 | 1999 |
| The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis TM Walker, P Miotto, CU Köser, PW Fowler, J Knaggs, Z Iqbal, M Hunt, ... The Lancet Microbe 3 (4), e265-e273, 2022 | 184 | 2022 |
Professor Sir Alimuddin ZumlaUniversity College LondonEmail verificata su ucl.ac.uk